Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients

• Verfasst von: Bärtsch, Marc-Andrea [VerfasserIn]
• Verfasst von: Schlenzka, Jana [VerfasserIn]
• Verfasst von: Kriegsmann, Katharina [VerfasserIn]
• Verfasst von: Klein, Stefan [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Wuchter, Patrick [VerfasserIn]
• Titel: Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients
• Titelzusatz: a subgroup analysis from the phase III trial ReLApsE
• Verf.angabe: Marc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, Julia Krzykalla, Natalia Becker, Katja Weisel, Richard Noppeney, Hans Martin, Hans W. Lindemann, Mathias Haenel, Axel Nogai, Christof Scheid, Hans Salwender, Roland Fenk, Ullrich Graeven, Peter Reimer, Martin Schmidt‐Hieber, Martin Goerner, Ingo G.H. Schmidt‐Wolf, Stefan Klein, Anthony D. Ho, Hartmut Goldschmidt, Patrick Wuchter
• E-Jahr: 2017
• Jahr: 31 March 2017
• Umfang: 9 S.
• Fussnoten: First published: 31 March 2017 ; Gesehen am 11.06.2018
• Titel Quelle: Enthalten in: European journal of haematology
• Ort Quelle: Oxford : Wiley-Blackwell, 1987
• Jahr Quelle: 2017
• Band/Heft Quelle: 99(2017), 1, Seite 42-50
• ISSN Quelle: 1600-0609
• DOI: doi:10.1111/ejh.12888
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: clinical trials
• Sach-SW: bone marrow transplantation
• Sach-SW: multiple myeloma
• K10plus-PPN: 1576216780

Abstract

Objective Analysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM). Methods Peripheral blood stem cells (PBSCs) were mobilized with high dose cyclophosphamide (2 g/m2 daily on days 1 and 2) and G-CSF plus pre-emptive/rescue plerixafor in RMM patients (first to third relapse) treated within the ReLApsE trial of the German-Speaking Myeloma Multicenter Group (GMMG). Results Mobilization was initiated with high-dose cyclophosphamide (HD-CY) and G-CSF in 30 patients. Fifteen patients received additional pre-emptive/rescue administration of plerixafor. Stem cell collection was successful (≥2×106 CD34+ cells per kg bw) in 77% (23/30 patients). Patients with prior high-dose melphalan collected a significantly lower median total number of PBSCs than patients without prior high-dose melphalan (3.3×106 vs 17×106 CD34+ cells/kg bw). Toxicity of HD-CY was frequent with 12 serious adverse events (SAE) in 37% of patients (11/30 patients). Infections accounted for the majority of SAE reports. In two patients, SAEs were lethal (septic shock). Conclusions These data proof feasibility of PBSC collection at relapse but emphasize the importance of collection and storage of additional PBSC transplants during first-line treatment when mobilization is more efficient and less toxic.